This suggests that sputum IL-1β or serum CRP concentrations could be used as biomarkers for identifying patients with COPD whose exacerbations are associated with bacterial infection and who may benefit from anti–IL-1 treatment approaches. The gene discussed is IL1A; the disease is chronic obstructive pulmonary disease.